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INTRODUCTION
Internationally, breast cancer is the most common female 
cancer, and the second most common cause of death in wom-
en. According to the National Cancer Institute, in 2011 more 
than 200,000 women were diagnosed with breast cancer in 
the United States [1]. Various treatment options are adopted 
for patients at various stages, and exhibiting particular molec-
ular subtypes of breast cancer. Surgical operations, including 
breast-conserving surgery and mastectomy, are definitive 
treatments for the disease. Adjuvant treatments such as radia-
tion therapy, chemotherapy, targeted therapy, and hormonal 
therapy, are prescribed to reduce disease recurrence and dis-
tant metastasis [2]. 
In the clinical setting, breast cancer is classified into four 
different molecular subtypes based on immunohistochemical 
detection of the expression of either the estrogen receptor 
(ER), progesterone receptor (PR), human epidermal growth 
factor receptor 2 (HER2), or mindbomb E3 ubiquitin protein 
ligase 1 antibody (MIB1) [3,4]. The majority of patients with 
breast cancer have luminal A or luminal B, hormone-respon-
sive breast cancers, and the standard treatment for which is to 
prescribe 5 to 10 years of tamoxifen or aromatase inhibitors as 
hormonal therapy. Of the two types, patients with luminal A 
breast cancer have a better prognosis than those with luminal 
B breast cancer [5]. HER2-positive breast cancer affects ap-
proximately 25% of all patients with breast cancer, and is 
treated with targeted therapy, for example, trastuzumab or 
lapatinib [6]. In contrast, triple negative breast cancer (TNBC) 
affects approximately 15% to 20% of all patients with breast 
cancer, and can only be treated systemically with chemother-
apy due to a lack of targetable ER, PR, and HER2 expression 
[7]. Chemotherapy treatment is able to achieve a pathological 
complete response in patients with TNBC when it is given in 
a neoadjuvant setting [3]. Although it has been suggested that 
a targeted therapy such as bevacizumab may be effective in 
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Internationally, breast cancer is the most common female cancer, 
and is induced by a combination of environmental, genetic, and 
epigenetic risk factors. Despite the advancement of imaging 
techniques, invasive sampling of breast epithelial cells is the only 
definitive diagnostic procedure for patients with breast cancer. 
To date, molecular biomarkers with high sensitivity and specifici-
ty for the screening and early detection of breast cancer are 
lacking. Recent evidence suggests that the detection of methyl-
ated circulating cell-free DNA in the peripheral blood of patients 
with cancer may be a promising quantitative and noninvasive 
method for cancer diagnosis. Methylation detection based on a 
multi-gene panel, rather than on the methylation status of a single 
gene, may be used to increase the sensitivity and specificity of 
breast cancer screening. In this review, the results of 14 relevant 
studies, investigating the efficacy of cell-free DNA methylation 
screening for breast cancer diagnosis, have been summarized. 
The genetic risk factors for breast cancer, the methods used for 
breast cancer detection, and the techniques and limitations re-
lated to the detection of cell-free DNA methylation status, have 
also been reviewed and discussed. From this review, we con-
clude that the analysis of peripheral blood or other samples to 
detect differentially methylated cell-free DNA is a promising 
technique for use in clinical settings, and may improve the sensi-
tivity of screening for both, early detection and disease relapse, 
and thus improve the future prognosis of patients with breast 
cancer. 
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treating TNBC, so far this not been possible [8]. Overall, (i.e., 
despite the use various therapies), the overall recurrence rate 
for patients with axillary node-negative breast cancer is ap-
proximately 25% after primary treatment, whilst a recurrence 
rate of up to 70% is observed for patients with axillary node-
positive disease [9]. 
GENETIC SUSCEPTIBILITY TO BREAST CANCER
Over the past decade, several breast cancer susceptibility 
genes of varying penetrance have been identified by linkage 
and large-scale, population-based genome-wide association 
studies [10]. These include such genes as BRCA1, BRCA2, 
TP53, PTEN, ATM, and CHEK2, all of which are involved in 
both cell cycle regulation and DNA repair pathways. For ex-
ample, DNA repair by homologous recombination is activated 
via phosphorylation of BRCA1 by ataxia telangiectasia mu-
tated kinase (ATM), in response to either ionizing radiation, 
ultraviolet irradiation, or other DNA-damaging agents [11]. 
When DNA damage is too severe to be repaired, phosphoryl-
ated BRCA1 forms complexes with BRCA2 and Rad51, and 
these subsequently interact with other proteins such as p53 
and CHEK2, which are checkpoint genes that regulate the cell 
cycle [11]. BRCA1 and BRCA2 mutations are the most fre-
quently identified mutations in hereditary breast cancers [12]. 
Up to 70% of breast cancers in patients with inherited BRCA1 
mutations are TNBC, whilst in contrast, inherited BRCA2 
mutations are associated with 87% of HER2 negative breast 
cancer [13]. Individuals carrying germline BRCA1 or BRCA2 
mutations have up to an 80% higher lifetime risk of develop-
ing breast cancer compared to individuals without any BRCA 
mutations [12]. 
Mutations in TP53 and PTEN are pleiotropic. Germline 
mutations in TP53 are often found in families with Li-Fraumeni 
syndrome (LFS), and are associated with several types of 
neoplasm. Patients with LFS are predisposed to the develop-
ment of a number of neoplasms, including not only breast 
cancer, but also brain tumors, soft tissue sarcoma, and other 
malignancies [14]. Similarly, germline mutations in PTEN are 
the most commonly observed mutations to cause Cowden 
syndrome, of which breast cancer may form a clinical feature 
[12]. The estimated breast cancer risks incurred by carriers of 
TP53 and PTEN mutations are 50% to 60% by the age of 45 
years, and 30% to 50% by the age of 70 years, respectively [12]. 
Amongst the various breast cancer susceptibility genes, muta-
tions in BRCA1, BRCA2, TP53, and PTEN are rare, but show 
high penetrance, and thus are included in most gene panels 
designed to predict breast cancer risk [10,15]. Mutations in 
moderate penetrance genes such as ATM and CHEK2 (such as 
1100decC in exon 10), are present in 2% to 3% of BRCA-neg-
ative familial breast cancers [12,16], and may result in an ap-
proximately 2-fold increase in the risk of developing breast 
cancer for female heterozygous carriers [12]. 
A novel, high-penetrance breast cancer susceptibility gene, 
RecQ helicase-like (RECQL), was recently identified [17], and 
confirmed to contribute to familial breast cancer by studies in 
two independent Chinese populations [18,19]. Although mu-
tation of this gene is very rare, the risk of developing breast 
cancer for RECQL carriers was found to be 5- and 16-fold 
higher in unselected Polish, and high-risk cases from Quebec, 
respectively [20]. Overall, mutations in the known susceptibil-
ity genes only account for 50% of hereditary breast cancer 
cases [17]. The factors responsible for the remaining 50% of 
hereditary breast cancer, and for the incidence of various spo-
radic breast cancers, are not clear. Since a complex network of 
genes is involved in the pathogenesis of breast cancer, many 
common genetic variations are identified in genome-wide as-
sociation studies aimed at identifying breast cancer suscepti-
bility genes. Certainly, data from exome-sequencing and ge-
nome-wide association studies imply that the pathogenesis of 
breast cancer may be polygenic [12,21]; however, the syner-
getic effects of low penetrance genetic variants on the devel-
opment of the disease is yet to be determined and validated. 
Thus, a current focus of research in this field is the identifica-
tion of high-sensitivity, highly specific molecular biomarkers 
for breast cancer, and the improvement of current genetic 
testing for breast cancer disease and susceptibility. 
CURRENT PROCEDURES FOR BREAST CANCER 
DETECTION AND DIAGNOSIS
Mammography and ultrasonography (USG) are commonly 
used imaging modalities for the detection of breast abnormal-
ities. The sensitivity of mammography is only moderate, and 
moreover is greatly affected by age and breast density [22]. 
Similarly, the use of USG for breast cancer screening incurs a 
high rate of false negative results, particularly in women with 
dense breast tissue. Thus, USG is generally used as a supple-
ment to mammography during screening to improve detec-
tion sensitivity, especially for women with dense breast tissue 
[23]. In contrast, magnetic resonance imaging (MRI) has been 
shown to have higher sensitivity in breast cancer detection re-
gardless of breast density; however, it is less likely to detect 
ductal carcinoma in situ, and is much more expensive than 
detection via mammography [23,24]. Moreover, there is limit-
ed evidence to suggest that the use of MRI and/or USG as 
screening tools can reduce mortality to the same extent as 
mammography [25]. As a result, mammography remains the 
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standard method for breast cancer screening, whilst USG and 
MRI are used as supplementary imaging tools for high-risk 
women with either dense breast tissue, or identified germline 
mutations [23,24].
Currently, the definitive diagnosis of breast cancer requires 
the sampling of breast epithelial cells by fine needle aspiration 
(FNA), and/or core biopsy guided stereotactically, ultrasoni-
cally, or where applicable, by MRI [26]. The sensitivity of FNA 
and core biopsy in detecting breast cancer is 82% and 93% re-
spectively, and this rate is increased to 97% when both FNA 
and core biopsy are conducted [26]. Due to its high sensitivity, 
core biopsy with subsequent immunohistochemical assess-
ment to detect breast cancer molecular subtypes is currently 
the ‘gold standard’ for breast tissue assessment and breast can-
cer therapy determination [26,27]. After the commencement 
of treatment, carcinoembryonic antigen (CEA) and CA15-3, 
which are the most widely used serum tumor biomarkers, are 
used in the clinical setting to monitor patient therapeutic re-
sponse and predict prognosis [28]. Although high concentra-
tions of CEA and CA15-3 are associated with poor prognosis 
and poor treatment response, limited evidence is available to 
support the use of these serum biomarkers for the routine 
surveillance for patients with breast cancer [28,29]. CA15-3 is 
a serum tumor marker not only for breast, but also for colon 
cancer, and similarly CEA is serum tumor marker for breast, 
colon, lung, and bladder cancer [30]. In addition, an increased 
concentration of CA15-3 only occurs in approximately 10% 
of patients with stage I breast cancer. Thus, early cancer detec-
tion is not feasible with these conventional serum tumor bio-
markers [28,30], rendering invasive screening and diagnostic 
procedures unavoidable at present, especially for asymptom-
atic patients. 
DNA METHYLATION STATUS IN BREAST CANCER
Recent studies have suggested that epigenetic mechanisms 
such as DNA methylation, microRNA activity, and histone 
acetylation, that cause gene silencing, may underly the devel-
opment of breast cancers of varying molecular subtypes. Of 
these mechanisms, DNA methylation is the predominant epi-
genetic modification found in human disease, particularly at 
regions enriched with cytosine and guanine dinucleotides 
(CpG) [31]. CpG regions are associated with gene promoters, 
that are located near transcription start sites in 70% of genes 
[32]. Unlike genetic mutation, DNA methylation is a revers-
ible process that alters gene expression patterns without modi-
fying the DNA sequence. Hypomethylation and hypermeth-
ylation states are both associated with human cancer, and 
have been shown to affect different regions of the genome de-
pendent on the cancer type (Figure 1) [33]. Hypomethylation 
is often detected in tumorous and metastatic tissues when 
compared with adjacent normal tissues [33], and generally in-
Figure 1. Hypomethylation and hypermethylation of human genome. (A) In normal cells, cytosine and guanine dinucleotides (CpG) islands in the pro-
moter region are unmethylated. (B) In cancer cells, promoter hypomethylation of oncogenic genes lead to transcription initiation. (C) Promoter hyper-
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creases the expression of oncogenes, activates transcription, 
and alters genome stability. Similarly, hypermethylation of 
CpG-rich genomic regions represses tumor-suppressing 
genes, predominantly (i.e., almost 80% of cases) via the most 
common form of DNA methylation, 5-methylcytosine [33-
35]. These epigenetic changes occur in normal tissues during 
the early stages of carcinogenesis, and eventually lead to the 
development of breast cancer [36]. Thus, changes to the meth-
ylation status of genes related to the epigenetic machinery of 
carcinogenesis may be useful molecular biomarkers for the 
early detection of breast cancer. 
The methods used to detect DNA methylation are similar 
to those used to detect single nucleotide polymorphisms or 
mutations in genomic DNA, i.e., polymerase chain reaction 
(PCR) and sequencing, respectively. However, to facilitate the 
detection of DNA methylation, DNA samples must be pre-
treated either by enzymatic digestion with restriction en-
zymes, or by bisulfite conversion [31]. During enzymatic di-
gestion, unmethylated CpG islands are recognized and 
cleaved by methylation-sensitive restriction enzymes, while 
methylated CpG islands remain intact. Methylation status can 
then be assessed via PCR using primers that only amplify re-
gions containing restriction sites [37]. This method is useful 
for identifying highly methylated genes, for example, those si-
lenced during X-chromosome inactivation [37]. Other meth-
ods, such as methylation-sensitive restriction enzyme diges-
tion with real-time quantitative PCR, or combined bisulfite 
restriction analysis, make use of methylation-sensitive restric-
tion enzymes to digest plasma DNA for subsequent real-time 
quantitative analysis [38,39]. However, incomplete enzymatic 
digestion of unmethylated CpG islands can lead to false posi-
tive results using these methods [37]. 
Bisulfite conversion is a chemical modification technique 
that changes cytosine bases to uracils via three processes: sul-
phonation, hydrolytic deamination, and alkali desulphonation 
[38]. Methylated CpG islands are resistant to these chemical 
modifications, and thus can be identified during PCR-based 
amplification of the genomic region of interest using primers 
specific for methylated and unmethylated CpG islands [37]. 
At unmethylated CpG islands, cytosines are converted to ura-
cils and bind their complementary bases (adenine) during 
PCR amplification, whereas methylated CpG islands resist 
conversion and instead bind guanines during amplification 
[37]. As discussed for enzymatic digestion, incomplete bisul-
fite conversion may lead to false positive results [38].
Various locus-based methods have been developed to es-
tablish the methylation status of bisulfite-treated DNA, in-
cluding methylation-specific PCR (MSP), quantitative real-
time MSP (qMSP), and pyrosequencing [40]. The use of next-
generation sequencing-based techniques such as whole ge-
nome shotgun bisulfite sequencing have recently become 
more common [40]. MSP is a qualitative, rapid, and robust 
detection method with high sensitivity and specificity, in 
which the amplification of a region of interest is achieved us-
ing primers specific to methylated and unmethylated DNA 
[37], and the resulting PCR-products are then visualized via 
gel electrophoresis [37]. qMSP was developed from MSP to 
allow quantification of the real-time methylation status of a 
given target gene, in addition to MSP-derived qualitative in-
formation [38]. Nevertheless, since methylation is both tissue-
specific and changes with time, qMSP is unable to generate 
quantitative information regarding the methylation status of 
each CpG site in a given target gene. Pyrosequencing is a real-
time, quantitative DNA-sequencing technique that detects the 
light signal generated by pyrophosphate released during the 
nucleotide incorporation enzymatic cascade [41]. As a result, 
it is able to obtain not only quantitative information, but can 
also establish the DNA methylation pattern at individual CpG 
sites by analyzing the cytosine to thymine ratio in amplified 
products [41]. 
These various methods for investigating the DNA methyla-
tion status of a given region of interest are particularly useful 
for studies that employ a candidate-gene approach, i.e., a hy-
pothesis-driven approach to study genes with known func-
tional roles related to a disease of interest [42]. Both enzymatic 
digestion and bisulfite conversion have recently been adapted 
for use in array hybridization and next-generation sequenc-
ing. This allows for the detection of the genome-wide methyl-
ation status of a given individual, and makes the techniques 
useful in epigenome-wide association studies (EWAS) that 
evaluate the role of common variants in complex diseases 
[40,43].
THE DNA METHYLATION STATUS OF 
CIRCULATING CELL-FREE DNA AS A CANCER 
DIAGNOSIS TOOL
The discovery of cell-free circulating DNA (cfDNA) in 
plasma and serum has led to investigation into its potential 
use as a biomarker for various diseases, including breast can-
cer. Although the molecular mechanism underlying cfDNA is 
still unclear, it is likely that a primary source of cfDNA may be 
the apoptosis of normal nucleated cells. The concentration of 
cfDNA is generally low in healthy individuals because it is 
rapidly removed from circulation by phagocytosis [44,45]. 
During tumorigenesis, excessive amounts of cfDNA are re-
leased by necrotic and apoptotic tumor cells, and also by lysed 
circulating tumor cells in the blood stream, causing a high 
16  Isabella Wai Yin Cheuk, et al. 
http://ejbc.kr https://doi.org/10.4048/jbc.2017.20.1.12
level of cfDNA to accumulate in patients with cancer [44]. 
Since cfDNA carries a methylation pattern identical to that of 
the genomic DNA in tumor cells, detection of cfDNA isolated 
from plasma or serum represents a potential noninvasive ap-
proach for quantifying both genetic and epigenetic informa-
tion in patients with cancer [45]. Thus, numerous studies in-
vestigating the efficacy and validity of using cfDNA for cancer 
detection have been conducted [44]. A summary of 14 such 
studies in patients with breast cancer is shown in Table 1. 
Each of these 14 published studies used a candidate-gene 
approach to investigate the potential of selected genes as mo-
lecular biomarkers for breast cancer detection according to 
differential methylation status of cfDNA between healthy in-
dividuals and patients with breast cancer [39,46-58]. Seven 
studies investigated the methylation status of a single candi-
date gene only between healthy individuals and patients with 
breast cancer, whilst the remaining studies analyzed between 
three and nine genes. Amongst all the evaluated candidate 
genes, adenomatous polyposis coli (APC), Ras association do-
main family 1 isoform A (RASSF1A), and retinoic acid recep-
tor β2 (RARβ2) were the three most extensively analyzed with 
regards to breast cancer development. All studies were case-
controlled, and included sample sizes ranging from 20 to 159 
patients with breast cancer. With the exception of the studies 
by Hagrass et al. [51] and Fu et al. [49], individuals with be-
nign breast conditions were used as controls. Three studies 
also included healthy individuals along with patients with be-
nign disease in the control groups, and one study included 45 
patients with gastric cancer in this group [39,48,53,57]. Bisul-
fide conversion-based methods were used in all studies except 
those by Ng et al. and Silva et al., in which enzymatic diges-
tion-based methods were instead employed [39,46-58]. 
Amongst all the bisulfite conversion-based techniques, MSP 
was the most frequently used to detect the methylation status 
of cfDNA [47-49,51,55,57]. Six studies used quantitative de-
tection methods to assess the cfDNA methylation status, one 
of which employed a commercially available assay [52-54,58]. 
Eight of the studies analyzed plasma samples, five studies ana-
lyzed serum samples, and one study analyzed both sample 
types in two cohorts of patients with cancer. Five of the four-
teen studies used a two-stage study design, including a discov-
ery cohort and independent validation cohort, to assess cfDNA 
methylation status in the context of breast cancer devel-
opment [39,46,50,52,54]. 
The results of the 14 studies promote the use of a multigene 
panel rather than a single gene as a molecular biomarker, to 
Table 1. Summary of published studies on investigating diagnosis value of circulating methylated DNA in breast cancer patients
Author Year Sample size Type of specimen Gene Method Reference
Chimonidou et al. 2013 Control, 60; cancer, 114 Plasma SOX17 qMSP [46]
Chimonidou et al. 2013 Control, 37; cancer, 27 (discovery), 46 
(metastatic), 123 (validation)
Plasma CST6 MSP [47]
Dulaimi et al. 2004 Control, 20; benign, 8; cancer, 34 Serum RASSF1A, APC, DAP-kinase MSP [48]
Fu et al. 2015 Benign, 60; cancer, 155 Plasma SOX17 MSP [49]
Guerrero-Preston et al. 2014 Control, 20 (discovery), 86 (validation); 
cancer, 20 (discovery), 154 (valida-
tion)
Plasma MAL, KIF1A, FKBP4, VGF, 
OGDHL
MSP [50]
Hagrass et al. 2014 Benign, 100; cancer, 120 Serum ESα MSP [51]
Hoque et al. 2006 Control, 76 (discovery), 38 (validation); 
cancer, 93 (discovery), 47 (validation)
Plasma APC, GSTP1, RASSF1A, 
RARβ2
qMSP [52]
Martínez-Galán et al. 2008 Control, 74; benign, 34; cancer, 106; 
postoperational, 60
Serum ESR1, APC, RARB, 14-3-3-σ, 
E-cadherin
qMSP [53]
Ng et al. 2011 Control, 60 (discovery), 20 (validation); 
breast cancer, 60 (discovery), 38 (vali-
dation); gastric cancer, 45 (discovery), 
20 (validation)
Plasma SLC19A3 MSRED-qPCR [39]
Radpour et al. 2011 Control, 30 (plasma, discovery); cancer, 
36 (plasma, discovery), 20 (serum, 
validation)
Plasma, serum APC, BIN1, BMP6, BRCA1, 
CST6, ESR-b, GSTP1, p16, 
p21, TIMP3
EpiTYPERTM assay [54]
Sharma et al. 2011 Control, 30; cancer, 100 Serum Maspin (SERPINB5) MSP [55]
Silva et al. 1999 Control, 17; cancer, 35 Plasma P16INK4a MSRE-PCR [56]
Skvortsova et al. 2006 Control, 10; benign, 15; cancer, 20 Plasma HIC-1, RASSF1A, RARβ2 MSP [57]
Yamamoto et al. 2012 Control, 87; cancer, 159 Serum GSTP1, RASSF1A, RARβ2 One-step MSP [58]
Each of these 14 published studies used a candidate-gene approach. 
qMSP=quantitative methylation-specific polymerase chain reaction; MSP=methylation-specific polymerase chain reaction; MSRED-qPCR=methylation-sensitive 
restriction enzyme digestion and real-time quantitative polymerase chain reaction; MSRE-PCR=methylation-sensitive restriction enzyme digestion real-time poly-
merase chain reaction.
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ensure high sensitivity and specificity during cancer detection. 
Sex determining region Y box 17 (Sox17) is a transcription 
factor essential for several developmental processes and for 
the regulation of stem cell function, and its methylation status 
with relation to breast cancer development was investigated 
by both Chimonidou et al. [46] and Fu et al. [49]. Whilst no 
promoter methylation was detected by Fu et al. in individuals 
with benign breast conditions, Chimonidou et al. detected 
SOX17 promoter methylation in 4.3% of control patients. A 
similar finding was also reported by Hoque et al. [52] regard-
ing the methylation status of RASSF1A, a tumor suppressor 
gene that regulates cell cycle progression and helps to main-
tain genetic stability [59]. Inactivation of RASSF1A via pro-
moter methylation has been reported in several primary tu-
mors, including breast tumors [59]. Amongst the four studies 
that included RASSF1A as a candidate gene, three identified 
no methylation in the control group, whereas one (by Hoque 
et al. [52]) found 5% of normal control patients to express 
methylated RASSF1A in plasma. Another study detected 20% 
and 49% methylation in at least one gene of a five-gene panel 
in the control group and cancer patient groups, respectively 
[50]. Thus, together these results demonstrate that careful 
consideration must be taken in selecting candidate genes as 
differential breast cancer biomarkers. 
Notably, the sensitivity of methylation-status detection was 
lower in plasma or serum samples than in primary tumor tis-
sues. For example, the sensitivity of using SOX17 methylation 
as a breast cancer diagnostic tool was decreased from 73% to 
58% when comparing paired tumor and plasma samples [49]. 
Similarly, the detection sensitivity reported by Dulaimi et al. 
[48] was 65% in tumor samples and only 56% in serum sam-
ples, a finding that studies by both Hoque et al. [52] and 
Yamamoto et al. [58] supported. The sensitivity of cancer detec-
tion using a multi-gene panel comprising RASSF1A and 
RARβ2 was reported to be as high as 95% for patients with 
breast cancer, and 100% for healthy controls [57]. Other stud-
ies reported similar findings when using multigene panels for 
cancer diagnosis [52,58]. Therefore, in addition to selecting 
appropriate candidate genes to increase specificity, the use of a 
multi-gene panel is recommended to enhance the sensitivity 
of cancer detection via differential cfDNA methylation levels. 
Finally, a minimum of 4 to 40 ng of DNA is recommended 
per sample input to ensure adequate PCR efficiency during 
cfDNA analysis, and to prevent the generation of false-nega-
tive results due to PCR-inhibition caused by low sample con-
centration [38]. Notably, of all the cfDNA studies that used bi-
sulfite-based techniques, only two specified the concentration 
of bisulfite-converted DNA used per reaction in their experi-
ments [47,51]. 
CONCLUSION
Several recently published studies show promising results in 
differentiating patients with cancer from healthy individuals 
according to cfDNA methylation patterns. Nevertheless, future 
replication studies are required to validate the prediction po-
tentials of the published epigenetic biomarkers with the use of 
new technologies, for example, next-generation DNA-methyl-
ation sequencing to obtain both quantitative and qualitative 
information. The first EWAS identified 250 differentially meth-
ylated CpG islands in the peripheral blood samples of high-
risk individuals that developed breast cancer during their post-
cancer monitoring, as compared to those that remained can-
cer-free [60]. Since these high-risk individuals had a family 
history of breast cancer, genetic, as well as environmental or 
other factors, may have contributed to these results. In add-
ition, the EWAS analyzed peripheral blood samples only, thus it 
is not clear whether the evaluation of cfDNA methylation sta-
tus using plasma or serum samples would have generated the 
same result. It is also important to note that the patient sample 
size of published studies thus far, (even including those with a 
two-stage study design), has been relatively small, limiting 
their resolution power. Thus, a sample size calculation model 
specifically designed for future EWAS has been proposed [61]. 
The sample type used for quantifying cfDNA in patients with 
cancer will also be critical to improve future studies. Serum has 
been shown to generally yield a higher concentration of cfDNA 
than plasma due to the lysis of leukocytes during clotting, such 
that the results generated using the two sample types are often 
incomparable. Furthermore, future studies should include not 
only a large cohort of patients with breast cancer, but also a 
large control cohort comprising healthy individuals both with 
and without benign conditions, to more accurately assess the 
potential of using cfDNA methylation status as an early cancer 
diagnosis tool. Given that the number of EWAS is increasing, a 
standardized set of guidelines for conducting these types of 
studies is needed so as to enable data pooling across studies, 
thereby overcoming the current limitations of this field of 
research imposed by the discussed small sample sizes. Thus, it 
is hoped that continued research into the use of differentially 
methylated cfDNA to identify breast cancer may lead to the 
development of a sensitive and specific molecular diagnostic 
test for use in the clinical setting, to screen for both early detec-
tion and patient relapse, and to thus improve prognosis for pa-
tients with breast cancer.
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